- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Myelin Basic Protein.
Displaying page 1 of 1.
EudraCT Number: 2005-001340-22 | Sponsor Protocol Number: BHT-3009-03 | Start Date*: 2005-08-12 |
Sponsor Name:Bayhill Therapeutics | ||
Full Title: BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | ||
Medical condition: Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarde... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FI (Prematurely Ended) SK (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001281-13 | Sponsor Protocol Number: KS-2004-06-SET | Start Date*: 2005-11-15 |
Sponsor Name:DSC Services, s.r.o. | ||
Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study) | ||
Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000283-41 | Sponsor Protocol Number: FUMAPMS2016 | Start Date*: 2016-09-12 | |||||||||||
Sponsor Name:Finn Sellebjerg | |||||||||||||
Full Title: Dimethyl fumarate treatment of primary progressive multiple sclerosis | |||||||||||||
Medical condition: Primary progressive multiple sclerosis (PPMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001724-35 | Sponsor Protocol Number: AMASCIS-02 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP) | |||||||||||||
Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL. | |||||||||||||
Medical condition: Moderate-severe ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003005-10 | Sponsor Protocol Number: IGR2012/1883 | Start Date*: 2013-06-06 | |||||||||||||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA | |||||||||||||||||||||||
Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.